瑞舒伐他汀联合依折麦布治疗急性冠状动脉综合征的效果观察

Clinical observation of rosuvastatin combined with ezetimibe in the treatment of acute coronary syndrome

目的:探讨瑞舒伐他汀联合依折麦布治疗急性冠状动脉综合征(ACS)的临床疗效及安全性。方法:ACS病人85例随机分为瑞舒伐他汀钙常规调脂组(对照组)以及瑞舒伐他汀钙联合依折麦布调脂组(联合组)。观察并比较2组病人治疗4周后血清学指标的变化,以及4周内主要的心血管事件发生率情况。结果:2组病人治疗后的三酰甘油、总胆固醇、低密度脂蛋白胆固醇等血脂指标与治疗前比较,均明显降低(P<0.05~P<0.01),联合组治疗后降低幅度大于对照组(P<0.01)。2组病人治疗后丙氨酸氨基转移酶与肌酸激酶均较治疗前降低(P<0.01),但2组间降低幅度差异无统计学意义(P>0.05)。联合组治疗4周内主要的心血管事件发生率低于对照组(P<0.05)。结论:瑞舒伐他汀联合依折麦布治疗ACS,有助于降低病人的血脂水平,减少主要心血管事件的发生情况,具有良好的疗效以及安全性。

Objective:To explore the clinical efficacy and safety of rosuvastatin combined with ezetimibe in the treatment of acute coronary syndrome(ACS).Methods:Eighty five patients with ACS were randomly divided into the rosuvastatin calcium group(control group)and rosuvastatin calcium combined with ezetimibe(combination group).The serology changes after4weeks of treatment,and incidence rate of major cardiovascular event during4weeks of treatment between two groups were compared.Results:Compared with before treatment,the levels of triacylglycerol,total cholesterol and low density lipoprotein cholestorol in two groups significantly decreased after treatment(P<0.05to P<0.01),the decreasing degree of lipid indexes in combination group was more than that in control group after treatment(P<0.01).Compared before treatment,the levels of alanine aminotransferase and creatine kinase in two groups decreased after treatment(P<0.01),the difference of the decreasing degree of which between two groups was not statistically significant(P>0.05).The incidence rate of cardiovascular event in combination group during4weeks of treatment was lower than that in control group(P<0.05).Conclusions:Rosuvastatin combined with ezetimibe in the treatment acute coronary syndrome can decrease the blood lipid level and incidence of major cardiovascular event,which has good efficacy and safety.